MX2016002795A - Compuestos de triazolona y usos de los mismos. - Google Patents

Compuestos de triazolona y usos de los mismos.

Info

Publication number
MX2016002795A
MX2016002795A MX2016002795A MX2016002795A MX2016002795A MX 2016002795 A MX2016002795 A MX 2016002795A MX 2016002795 A MX2016002795 A MX 2016002795A MX 2016002795 A MX2016002795 A MX 2016002795A MX 2016002795 A MX2016002795 A MX 2016002795A
Authority
MX
Mexico
Prior art keywords
pparî
cancers
directed
invention disclosed
melanoma
Prior art date
Application number
MX2016002795A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas Simon Stock
Austin Chih-Yu Chen
Yalda Mostofi Bravo
Jason Duarte Jacintho
Original Assignee
Inception 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inception 2 Inc filed Critical Inception 2 Inc
Publication of MX2016002795A publication Critical patent/MX2016002795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2016002795A 2013-09-06 2014-09-04 Compuestos de triazolona y usos de los mismos. MX2016002795A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874956P 2013-09-06 2013-09-06
PCT/US2014/054108 WO2015035059A1 (en) 2013-09-06 2014-09-04 Triazolone compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2016002795A true MX2016002795A (es) 2016-05-26

Family

ID=52628929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002795A MX2016002795A (es) 2013-09-06 2014-09-04 Compuestos de triazolona y usos de los mismos.

Country Status (13)

Country Link
US (1) US9776976B2 (https=)
EP (1) EP3041826A4 (https=)
JP (1) JP2016529311A (https=)
KR (1) KR20160048988A (https=)
CN (1) CN105579440A (https=)
AU (1) AU2014315151A1 (https=)
CA (1) CA2921420A1 (https=)
EA (1) EA201690230A1 (https=)
IL (1) IL244383A0 (https=)
MX (1) MX2016002795A (https=)
PE (1) PE20160880A1 (https=)
SG (1) SG11201601066VA (https=)
WO (1) WO2015035059A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
CN109476646A (zh) 2016-07-12 2019-03-15 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
GB201910037D0 (en) 2019-07-12 2019-08-28 Syngenta Crop Protection Ag Microbiocidal compounds
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379B (zh) * 2022-01-20 2025-06-27 哈尔滨三联药业股份有限公司 海因类化合物及其医药用途

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK160611C (da) 1979-09-04 1991-09-16 Bristol Myers Squibb Co Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider
US4487773A (en) 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
IN158869B (https=) 1981-03-18 1987-02-07 Ici Plc
DD160447A1 (de) 1981-03-26 1983-08-03 Johannes Dost Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
DE3267110D1 (de) 1981-05-18 1985-12-05 Ici Plc Amidine derivatives
DE3238590A1 (de) 1982-10-19 1984-04-19 VEB Fahlberg-List Chemische und pharmazeutische Fabriken, DDR 3013 Magdeburg Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
NL8204109A (nl) 1982-10-25 1984-05-16 Fahlberg List Veb Herbicide middelen, die 1.2.4-triazolinon-(5)-verbindingen bevatten.
FR2535168B1 (fr) 1982-10-29 1985-08-09 Fahlberg List Veb Agents herbicides a base de 1, 2, 4-triazolinone 5
JPS60215675A (ja) 1984-04-09 1985-10-29 Nippon Nohyaku Co Ltd オキサジアゾリノン誘導体及びトリアゾリノン誘導体並びにその製造方法並びに昆虫成長制御剤
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DE3934081A1 (de) 1989-10-12 1991-04-18 Bayer Ag Sulfonylaminocarbonyltriazolinone
CA2073005C (en) 1990-09-06 1998-11-10 Alan Stobie Antimuscarinic bronchodilators
JP2772875B2 (ja) 1991-05-14 1998-07-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法及び写真用漂白定着組成物
SG47949A1 (en) 1991-10-30 1998-04-17 Astra Ab 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
WO1993021181A1 (en) 1992-04-15 1993-10-28 Merck Sharp & Dohme Limited Azacyclic compounds
DE4224929A1 (de) 1992-07-28 1994-02-03 Bayer Ag Heterocyclyltriazolinone
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
IT1256387B (it) 1992-11-13 1995-12-04 Acraf Procedimento per preparare triazoloni
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE4343595A1 (de) 1993-12-21 1995-06-22 Bayer Ag Verfahren zur Herstellung von Sulfonylaminocarbonyltriazolinonen
US5550118A (en) 1994-01-31 1996-08-27 Eli Lilly And Company Polyhydronorharman synthase inhibitors
DE4404848A1 (de) 1994-02-16 1995-08-17 Hoechst Ag Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9418545D0 (en) 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
JPH08157473A (ja) 1994-10-06 1996-06-18 Nissan Chem Ind Ltd ピラゾール系チアゾリジン類
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
IN183333B (https=) 1995-03-15 1999-11-20 Indian Drugs & Pharma
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
DE19521162A1 (de) 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
GB9513121D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513117D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
EP0784053A1 (de) 1996-01-15 1997-07-16 Degussa Aktiengesellschaft Verfahren zur Herstellung von Triazolinonherbiziden
DE19601189A1 (de) 1996-01-15 1997-07-17 Degussa Verfahren zur Herstellung von 1,2,4-Triazolin-3(2H)-onen
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
DE69736390T2 (de) 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
WO1999003835A1 (en) 1997-07-18 1999-01-28 Nippon Kayaku Kabushiki Kaisha Aromatic ketone derivatives and uses thereof
EP1049693A1 (en) 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
CA2333964A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Aza-heterocyclic compounds used to treat neurological disorders and hair loss
CN1295561A (zh) 1998-06-03 2001-05-16 Gpinil控股公司 N－杂环羧酸或羧酸等排物的n－结合氨磺酰
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
CA2336152A1 (en) 1998-08-14 2000-02-24 Gpi Nil Holdings, Inc. Ureas and carbamates of n-heterocyclic carboxylic acids and isosteres for vision and memory disorders
SE9802937D0 (sv) 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
AU1345600A (en) 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
DE19955662B4 (de) 1999-11-19 2011-03-31 Arysta LifeScience North America, Herbizide auf Basis von Carbamoyltriazolinon
EP1110958A1 (en) 1999-12-20 2001-06-27 Ucb, S.A. Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU6594401A (en) 2000-05-24 2001-12-03 Bayer Aktiengesellschaft 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
CA2469821C (en) 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
ATE403426T1 (de) 2002-02-07 2008-08-15 Univ Missouri Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
EP1513829A2 (en) 2002-06-14 2005-03-16 Syngenta Participations AG Nicotinoyl derivatives as herbicidal compounds
WO2004032846A2 (en) 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
PL375889A1 (en) 2002-10-11 2005-12-12 Cytokinetics, Inc. Compounds for treating cellular proliferative diseases, compositions containing them and their application
WO2004032879A2 (en) 2002-10-11 2004-04-22 Cytokinetics, Inc. Compounds, compositions, and methods
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CA2521396A1 (en) 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
DE602004025220D1 (de) 2003-04-11 2010-03-11 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077178A2 (en) 2004-02-16 2005-08-25 Syngenta Participations Ag Herbicidal composition
EP1720860A1 (en) 2004-02-18 2006-11-15 AstraZeneca AB Triazole compounds and their use as metabotropic glutamate receptor antagonists
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2006010545A1 (en) 2004-07-27 2006-02-02 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
CN1315810C (zh) 2004-08-30 2007-05-16 北京理工大学 哌嗪桥联他克林双体衍生物及其合成方法
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
DE602006014502D1 (de) 2005-01-14 2010-07-08 Janssen Pharmaceutica Nv Pyrazolopyrimidine als zellzyklus-kinasehemmer
WO2006078698A1 (en) 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
PE20061041A1 (es) 2005-01-28 2006-10-12 Lilly Co Eli Formulaciones y regimen de dosificacion para moduladores alfa de ppar
JP5289043B2 (ja) 2005-04-12 2013-09-11 ヴィコール・ファルマ・アーベー 新規な三環系アンジオテンシンｉｉアゴニスト
CN101213729B (zh) 2005-04-28 2013-06-12 株式会社电装 交流电动机
DE102005025992A1 (de) 2005-06-07 2007-01-11 Lanxess Deutschland Gmbh Verfahren zur Herstellung von substituierten Azolen
WO2007019397A2 (en) 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
EP1953148B1 (en) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
DE102006003444A1 (de) 2006-01-25 2007-07-26 Lanxess Deutschland Gmbh Verfahren zur Herstellung von iodierten Azolen
GB2435829A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Pyrimidinyl-2-piperazine compounds for use in disorders related to food intake
GB2435828A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted phenyl-piperazine compounds for treatment of food related disorders
GB2435827A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted piperazine compounds for the treatment of food related disorders
US7674811B2 (en) 2006-03-14 2010-03-09 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
BRPI0709110A2 (pt) 2006-03-23 2011-06-28 Prolysis Ltd agentes antibacterianos
CA2647423C (en) 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Triazolone derivative
DE102006023337A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006032164A1 (de) 2006-07-12 2008-01-24 Bayer Cropscience Ag Substituierte Furyl-sulfonylamino(thio)carbonyl-triazolin(thi)one
US7994321B2 (en) 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
CN101535303B (zh) 2006-08-15 2012-07-18 诺瓦提斯公司 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物
CA2678846A1 (en) 2007-02-23 2008-08-28 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
BRPI0809617A2 (pt) 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
JP2010524861A (ja) 2007-04-20 2010-07-22 メルク フロスト カナダ リミテツド ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤としての新規な複素環式芳香族化合物
WO2009017863A2 (en) 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
ES2617305T3 (es) 2007-07-17 2017-06-16 Acea Biosciences, Inc. Compuestos heterocíclicos y usos como agentes anticancerosos
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US8222254B2 (en) 2007-08-07 2012-07-17 Prosarix Limited 1, 2, 4-triazole derivatives as serotonergic modulators
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
NZ585704A (en) 2007-12-10 2012-08-31 7Tm Pharma As Modulators of cannabinoid receptor CB1 for treating obesity
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
SI2291080T1 (sl) 2008-05-14 2015-11-30 The Scripps Research Institute Novi modulatorji sfingosinskih fosfatnih receptorjev
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
CN101643451B (zh) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
JP2011231015A (ja) 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
NZ592603A (en) 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
WO2010139966A1 (en) 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
WO2011058478A1 (en) 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
KR101169359B1 (ko) 2010-01-29 2012-07-30 주식회사 레고켐 바이오사이언스 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
ES2509951T3 (es) 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
EP2371823A1 (de) 2010-04-01 2011-10-05 Bayer CropScience AG Cyclopropyl-substituierte Phenylsulfonylamino(thio)carbonyltriazolinone, ihre Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2012027482A2 (en) * 2010-08-24 2012-03-01 Georgetown University Compounds, compositions and methods related to ppar antagonists
WO2012037299A2 (en) 2010-09-17 2012-03-22 Glaxosmithkline Llc Fatty acid synthase inhibitors
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
WO2013134562A1 (en) * 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof

Also Published As

Publication number Publication date
EP3041826A4 (en) 2017-02-15
SG11201601066VA (en) 2016-03-30
CA2921420A1 (en) 2015-03-12
WO2015035059A1 (en) 2015-03-12
JP2016529311A (ja) 2016-09-23
CN105579440A (zh) 2016-05-11
US20160194292A1 (en) 2016-07-07
EA201690230A1 (ru) 2016-07-29
IL244383A0 (en) 2016-04-21
EP3041826A1 (en) 2016-07-13
PE20160880A1 (es) 2016-09-22
AU2014315151A1 (en) 2016-03-03
KR20160048988A (ko) 2016-05-04
US9776976B2 (en) 2017-10-03

Similar Documents

Publication Publication Date Title
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
NZ722345A (en) Pyrazolone compounds and uses thereof
CY1124793T1 (el) Ακρυλαμιδια πυρρολο[2,3-d]πυριμιδινυλιου, πυρρολo[2,3-β]πυραζινυλιου και πυρρολο[2,3-d]πυριδινυλιου
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
CY1119714T1 (el) Ενωσεις αναστολεων
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
MX2015011245A (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
TR201906470T4 (tr) İmmünomodülatörler.
PH12019500480A1 (en) Pyridine compound
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
MX2016007311A (es) Metodos para tratar canceres.
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
EA201690322A1 (ru) Терапевтически активные соединения и способы их применения
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
NZ726365A (en) Combinations for treating cancers
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA027986B9 (ru) Соединения триазолона и их применение
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201591649A1 (ru) Составы с органическими соединениями
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом